News

Double Shot Gives Spark Therapeutics a Jolt

Double Shot Gives Spark Therapeutics a Jolt

By Rich Kirkner | July 26, 2017

Spark Therapeutics is riding a double shot of positive news about its gene therapy treatment for RPE65-mediated inherited retinal disorders that’s given its stock a…

Read More
Inotek May Be for Sale, But Who Will Buy?

Inotek May Be for Sale, But Who Will Buy?

By Steve Lenier | July 19, 2017

With another failed trial of its glaucoma candidate trabodenoson in hand, Inotek Pharmaceuticals Corp. is pondering options that could include selling the company, but finding…

Read More
AGTC Makes Moves with Cash in Hand

AGTC Makes Moves with Cash in Hand

By Rich Kirkner | July 11, 2017

As Applied Genetic Technologies Corporation (AGTC) heads into the summer with encouraging results for two of its lead candidates using the adeno-associated virus-based gene technology…

Read More
OIS-Eye-On-Five

Eye on Five – June Edition

By Rich Kirkner | July 5, 2017

Novartis Reports Positive Phase III Results for RTH258 Novartis reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints of non-inferiority compared…

Read More
OIS-Index-Article

First-Half Performance: OIS Index Tracks US Stock Market but Lags Healthcare Benchmarks

By Michael Lachman | July 5, 2017

We see ophthalmology as one of the more innovative specialties in healthcare, but does that excitement translate to the public markets? In October, we launched…

Read More
Is AMD Drug-Treatment Landscape Shifting?

Is AMD Drug-Treatment Landscape Shifting?

By Rich Kirkner | June 28, 2017

When Novartis last week announced positive outcomes from two Phase III trials for new age-related macular degeneration (AMD) drug brolucizumab (RTH258), it seemed the other…

Read More
With CE Mark for Glaucoma Microsensor in Pocket, Implandata Looks to US

With CE Mark for Glaucoma Microsensor in Pocket, Implandata Looks to US

By Rich Kirkner | June 21, 2017

Now that the Implandata Ophthalmic Products has received approval to commercialize its implantable glaucoma-monitoring device in the European Union, it’s setting its sights on lining…

Read More
How Mynosys Is Gearing Up to Take on Femto

How Mynosys is Gearing Up to Take on Femto

By Rich Kirkner | June 14, 2017

Now that Mynosys Cellular Devices has received FDA 510(k) clearance for its Zepto Capsulotomy System for cataract surgery, the company is planning its US launch…

Read More
MIGS and the Future of Glaucoma Treatment: New Insights

MIGS and the Future of Glaucoma Treatment: New Insights

By Steve Lenier | June 7, 2017

Microinvasive glaucoma surgery (MIGS) pioneer Reay H. Brown, MD, has long advocated that surgery will be the best treatment option for glaucoma once safety and…

Read More
OIS-Eye-On-Five

Eye on Five – May Edition

By Rich Kirkner | June 1, 2017

Alcon Launches Multifocal Toric IOL at ASCRS Alcon seized the platform of ASCRS 2017 to launch its AcrySof IQ ReSTOR +2.5 multifocal toric intraocular lens…

Read More
OIS-Index-Article

OIS Index Declines in May Despite Positive Pipeline News from Aerie

By Michael Lachman | June 1, 2017

In October, we launched the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our sector. Our goal is to…

Read More
Déjà vu: Aerie Announces Mercury 2 Results, Stock Jumps

Déjà vu: Aerie Announces Mercury 2 Results, Stock Jumps

By Rich Kirkner | May 31, 2017

With the recent report of successful top-line Phase III results of its fixed-dose glaucoma candidate Roclatan, Aerie Pharmaceuticals Inc. has seen its stock price soar…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.